Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MPN Congress 2022 | Combining novel agents for treating myelofibrosis

Naveen Pemmaraju • 24 Nov 2022
MPN Congress 2022
Myelofibrosis Myeloproliferative Neoplasms Imetelstat Luspatercept Momelotinib Navitoclax Navtemadlin Pacritinib Parsaclisib Pelabresib Ruxolitinib

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives a presentation on the combining novel agents for treating myelofibrosis (MF) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

More from Naveen Pemmaraju

The value and interactive format of the MPN Workshop of the Carolinas
6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju • 22 Aug 2025
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
2:17
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
Naveen Pemmaraju • 31 May 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Naveen Pemmaraju • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Naveen Pemmaraju • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Naveen Pemmaraju • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Naveen Pemmaraju • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals